Gilead Sciences (GILD) revenue breakdown

Healthcare · Drug Manufacturers - General · Market cap $184.1B

By product, Biktarvy is the largest at 49% of fiscal 2025 revenue; Yescarta grew fastest, 22% a year over 6 years.

By region, U.S. is the largest at 71% of fiscal 2025 revenue, growing 1% a year over 9 years.

Revenue by product

Fiscal years, as Gilead Sciences reports them in its 10-K filings; fiscal 2025 total $29.4B.

Products	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Share
Biktarvy	—	—	—	$4.7B	$7.3B	$8.6B	$10.4B	$11.8B	$13.4B	$14.3B	49%
Descovy	—	—	—	$1.5B	$1.9B	$1.7B	$1.9B	$2.0B	$2.1B	$2.8B	9%
Genvoya	—	—	—	$3.9B	$3.3B	$2.9B	$2.4B	$2.1B	$1.8B	$1.5B	5%
Yescarta	—	—	—	$456M	$563M	$695M	$1.2B	$1.5B	$1.6B	$1.5B	5%
Trodelvy	—	—	—	—	$49M	$380M	$680M	$1.1B	$1.3B	$1.4B	5%
Sofosbuvir/Velpatasvir	—	—	—	$2.0B	$1.6B	$1.5B	$1.5B	$1.5B	$1.6B	$1.3B	4%
Odefsey	—	—	—	$1.7B	$1.7B	$1.6B	$1.5B	$1.4B	$1.3B	$1.2B	4%
Vemlidy	—	—	—	$488M	$657M	$814M	$842M	$862M	$959M	$1.1B	4%
Veklury	—	—	—	—	$2.8B	$5.6B	$3.9B	$2.2B	$1.8B	$911M	3%
Other Liver Disease	—	—	—	—	—	—	$426M	$385M	$467M	$874M	3%
Royalty, contract and other revenues	$437M	$445M	$450M	$330M	$334M	$297M	$299M	$182M	$144M	$527M	2%
AmBisome	—	—	—	$407M	$436M	$540M	$497M	$492M	$533M	$509M	2%
Other HIV	—	—	—	$47M	$407M	$195M	$530M	$401M	$434M	$500M	2%
Symtuza - Revenue share	—	—	—	$379M	$488M	$531M	$530M	$529M	$592M	$495M	2%
Tecartus	—	—	—	—	$44M	$176M	$299M	$370M	$403M	$344M	1%
Other	—	—	—	$203M	$276M	$281M	$449M	$367M	$356M	$290M	1%
Product	$30.0B	$25.7B	—	—	—	—	—	—	—	—	—
HIV Products, Genvoya	—	—	$4.6B	—	—	—	—	—	—	—	—
HIV Products, Truvada	—	—	$3.0B	—	—	—	—	—	—	—	—
Sofosbuvir/Velpatasvir	—	—	$2.0B	—	—	—	—	—	—	—	—
HIV Products, Odefsey	—	—	$1.6B	—	—	—	—	—	—	—	—
HIV Products, Descovy	—	—	$1.6B	—	—	—	—	—	—	—	—
Ledipasvir/Sofosbuvir	—	—	$1.2B	—	—	—	—	—	—	—	—
HIV Products, Atripla	—	—	$1.2B	—	—	—	—	—	—	—	—
HIV Products, Biktarvy	—	—	$1.2B	—	—	—	—	—	—	—	—
Letairis	—	—	$943M	—	—	—	—	—	—	—	—
Ranexa	—	—	$758M	—	—	—	—	—	—	—	—
HIV Products, Complera/Eviplera	—	—	$653M	—	—	—	—	—	—	—	—
HIV Products, Stribild	—	—	$644M	—	—	—	—	—	—	—	—
Atripla	—	—	—	$600M	—	—	—	—	—	—	—
Other HCV	—	—	$498M	—	—	—	—	—	—	—	—
Other Products, AmBisome	—	—	$420M	—	—	—	—	—	—	—	—
Truvada	—	—	—	$2.8B	$1.4B	$371M	—	—	—	—	—
Other Products, Vemlidy	—	—	$321M	—	—	—	—	—	—	—	—
Other Products, Viread	—	—	$307M	—	—	—	—	—	—	—	—
Cell Therapy Products, Yescarta	—	—	$264M	—	—	—	—	—	—	—	—
Complera/Eviplera	—	—	—	$406M	$269M	$258M	—	—	—	—	—
Other	—	—	$218M	—	—	—	—	—	—	—	—
Ranexa	—	—	—	$216M	—	—	—	—	—	—	—
Ledipasvir/Sofosbuvir	—	—	—	$643M	$272M	$212M	—	—	—	—	—
Other HCV	—	—	—	$328M	$193M	$207M	—	—	—	—	—
Letairis	—	—	—	$618M	$314M	$206M	—	—	—	—	—
Stribild	—	—	—	$369M	$196M	$189M	—	—	—	—	—
Other Products, Zydelig	—	—	$133M	—	—	—	—	—	—	—	—
Viread	—	—	—	$243M	$185M	$111M	—	—	—	—	—
Zydelig	—	—	—	$103M	—	—	—	—	—	—	—
Revenue share - Symtuza	—	—	$79M	—	—	—	—	—	—	—	—
Other HIV	—	—	$61M	—	—	—	—	—	—	—	—
Other HB/HDV	—	—	—	$11M	$18M	$44M	—	—	—	—	—

Revenue by region

Fiscal years, as Gilead Sciences reports them in its 10-K filings; fiscal 2025 total $29.4B.

Regions	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	Share
U.S.	$19.4B	$18.2B	$16.3B	$16.6B	$18.2B	$19.3B	$18.9B	$19.4B	$20.6B	$20.9B	71%
Europe	$6.4B	$5.3B	$4.0B	$3.8B	$4.1B	$4.9B	$4.5B	$4.3B	$4.6B	$5.1B	17%
Rest of World	$4.7B	$2.6B	$1.9B	$2.0B	$2.3B	$3.2B	$3.9B	$3.4B	$3.5B	$3.5B	12%

Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GILD.

Open GILD in Investingly

Questions

Where does Gilead Sciences make its money?

In fiscal 2025, by product: Biktarvy $14.3B, Descovy $2.8B, Genvoya $1.5B, Yescarta $1.5B, Trodelvy $1.4B.

From Gilead Sciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.